Daewoong Co., Ltd.

Equities

A003090

KR7003090008

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
18,180 KRW +1.56% Intraday chart for Daewoong Co., Ltd. +5.70% -11.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge MT
Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia MT
Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023. CI
Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023. CI
Daewoong Co., Ltd.'s Equity Buyback announced on July 27, 2023, has closed with 690,630 shares, representing 1.66% for KRW 9,997.24 million. CI
Zydus Unit, Daewoong Pharma to Co-Develop, Commercialize Leuprolide Acetate in US MT
Daewoong Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023. CI
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia MT
Daewoong Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Daewoong Pharmaceutical's Nabota Surpasses 600,000 Customers in the US MT
Daewoong Co., Ltd. announces an Equity Buyback for KRW 10,000 million worth of its shares. CI
Daewoong Co., Ltd. authorizes a Buyback Plan. CI
Avacta sees shares rise on new equity payment for South Korea venture AN
Daewoong Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
An Unknown buyer completed the acquisition of 66.2% stake in Palmpack Co., Ltd. from Daewoong Co., Ltd.. CI
Sonoma Pharmaceuticals Signs Distribution Deal With Daewoong Pharmaceutical to Sell Skin Products in South Korea MT
Oncorus, Daewoong Pharmaceutical to Develop Lipid Nanoparticle Formulations for mRNA Drug Candidate; Shares Surge MT
Daewoong Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Daewoong Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Daewoong Pharmaceutical Aims to Expand Reach of Nabota Beyond Cosmetic Applications MT
Avacta JV Extends Drug Manufacturing Agreement With GenScript MT
Daewoong Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart Daewoong Co., Ltd.
More charts
Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
18,180 KRW
Average target price
25,000 KRW
Spread / Average Target
+37.51%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A003090 Stock
  4. News Daewoong Co., Ltd.
  5. Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia